BS_84XCR9GG
high-grade glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- high-grade glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- high-grade glioma
- overall_survival_months
- 24.605781865965834
- age_years
- 6.501
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.621
- G2M_CHECKPOINT+0.583
- MYC_TARGETS_V2+0.507
- MYC_TARGETS_V1+0.489
- MTORC1_SIGNALING+0.429
- ANGIOGENESIS+0.381
- TNFA_SIGNALING_VIA_NFKB+0.357
- UNFOLDED_PROTEIN_RESPONSE+0.352
- INFLAMMATORY_RESPONSE+0.273
- TGF_BETA_SIGNALING+0.218
Top 10 suppressed
- BILE_ACID_METABOLISM-0.320
- MYOGENESIS-0.279
- XENOBIOTIC_METABOLISM-0.247
- ADIPOGENESIS-0.215
- OXIDATIVE_PHOSPHORYLATION-0.214
- ESTROGEN_RESPONSE_EARLY-0.195
- HEDGEHOG_SIGNALING-0.178
- HEME_METABOLISM-0.176
- PEROXISOME-0.168
- FATTY_ACID_METABOLISM-0.155
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-D8-A1XK-01A-21R-A14M-07 | — | E | 0.858 |
| 2 | SRR934852 | — | — | 0.845 |
| 3 | TCGA-BH-A18V-01A-11R-A12D-07 | — | E | 0.838 |
| 4 | E1B8B320-25EE-4B2C-B705-AB50C3EF5E29 | — | — | 0.836 |
| 5 | ERR2208969 | — | — | 0.834 |
| 6 | 4d36189e-fe88-4cfb-970b-a51b8e9e0783 | — | — | 0.833 |
| 7 | SRR8943028 | — | — | 0.833 |
| 8 | SRR934813 | — | — | 0.831 |
| 9 | 8ACC0F29-A39E-4C1C-A04C-ED6E5FA80C24 | — | — | 0.821 |
| 10 | SAMN03290909 | — | — | 0.818 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.621 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.583 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.507 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.489 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.429 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.381 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.357 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.352 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.273 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.218 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.212 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.201 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.197 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.197 | Inavolisib | — uncovered |
| HYPOXIA | 0.197 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.188 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.174 | Cobimetinib | — uncovered |
| NOTCH_SIGNALING | 0.172 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.161 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.156 | Inavolisib | — uncovered |